全文获取类型
收费全文 | 79850篇 |
免费 | 3804篇 |
国内免费 | 326篇 |
专业分类
耳鼻咽喉 | 1035篇 |
儿科学 | 2146篇 |
妇产科学 | 1985篇 |
基础医学 | 10546篇 |
口腔科学 | 2957篇 |
临床医学 | 5799篇 |
内科学 | 19667篇 |
皮肤病学 | 1646篇 |
神经病学 | 6815篇 |
特种医学 | 2439篇 |
外国民族医学 | 6篇 |
外科学 | 9405篇 |
综合类 | 424篇 |
一般理论 | 28篇 |
预防医学 | 8410篇 |
眼科学 | 1305篇 |
药学 | 5331篇 |
中国医学 | 303篇 |
肿瘤学 | 3733篇 |
出版年
2023年 | 541篇 |
2022年 | 1006篇 |
2021年 | 2188篇 |
2020年 | 1171篇 |
2019年 | 1872篇 |
2018年 | 3915篇 |
2017年 | 2398篇 |
2016年 | 1789篇 |
2015年 | 1893篇 |
2014年 | 2611篇 |
2013年 | 3465篇 |
2012年 | 5307篇 |
2011年 | 5660篇 |
2010年 | 3050篇 |
2009年 | 2545篇 |
2008年 | 4554篇 |
2007年 | 4702篇 |
2006年 | 4341篇 |
2005年 | 4353篇 |
2004年 | 3956篇 |
2003年 | 3700篇 |
2002年 | 3459篇 |
2001年 | 1832篇 |
2000年 | 1943篇 |
1999年 | 1583篇 |
1998年 | 584篇 |
1997年 | 385篇 |
1996年 | 374篇 |
1995年 | 321篇 |
1994年 | 270篇 |
1993年 | 276篇 |
1992年 | 799篇 |
1991年 | 637篇 |
1990年 | 612篇 |
1989年 | 526篇 |
1988年 | 469篇 |
1987年 | 488篇 |
1986年 | 424篇 |
1985年 | 373篇 |
1984年 | 273篇 |
1983年 | 235篇 |
1979年 | 199篇 |
1978年 | 173篇 |
1977年 | 149篇 |
1975年 | 176篇 |
1974年 | 181篇 |
1973年 | 169篇 |
1972年 | 168篇 |
1971年 | 163篇 |
1968年 | 150篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
995.
996.
997.
Vicente Valentín Maganto Carlos Camps Herrero Joan Carulla Torrent Javier Cassinello Espinosa Javier Dorta Delgado Carlos Jara Sánchez José Andrés Moreno Nogueira 《Clinical & translational oncology》2005,7(5):205-212
INTRODUCTION: Oral trans-mucosal fentanyl citrate (OTFC) is the one drug specifically developed for the management of breakthrough pain. This study assesses the long-term safety and efficacy of OTFC standard clinical conditions. Patients and methods. Six-month observational study performed on cancer patients with episodes of breakthrough pain. Safety was assessed by recording the advent of adverse events and efficacy by the evaluating the intensity of breakthrough pain. RESULTS: 174 cancer patients were recruited into the study. All adverse reactions reported were mild or moderate. OTFC was significantly faster (time to the commencement of pain relief: 12.7 +/- 11.4 vs 32.7 +/- 18.4 minutes; p < 0.001) and potent (post-treatment pain intensity: 3.4 +/- 1.5 vs 4.3 +/- 1.5; p < 0.001) than the previously-used drugs. CONCLUSIONS: This observational study confirms the good safety profile of OTFC as well as its effectiveness over long-term period treatment of breakthrough pain. 相似文献
998.
Michel Ducreux Marc Ychou Agnès Laplanche Erick Gamelin Philippe Lasser Fares Husseini Fran?ois Quenet Frédéric Viret Jacques-Henri Jacob Valérie Boige Dominique Elias Jean-Robert Delperro Monique Luboinski 《Journal of clinical oncology》2005,23(22):4881-4887
PURPOSE: Isolated hepatic metastases of colorectal cancer constitute a frequent and serious therapeutic problem that has led to the evaluation of hepatic arterial infusion (HAI) of different drugs. Oxaliplatin combined with fluorouracil (FU) and leucovorin is effective in the treatment of colorectal cancer. In this context, a phase II study was conducted to evaluate concomitant administration of oxaliplatin by HAI and intravenous (IV) FU plus leucovorin according to the LV5FU2 protocol (leucovorin 200 mg/m(2), FU 400 mg/m(2) IV bolus, FU 600 mg/m(2) 22-hour continuous infusion on days 1 and 2 every 2 weeks). PATIENTS AND METHODS: Patients had metastatic colorectal cancer that was restricted to the liver and inoperable. The patients were not to have previously received oxaliplatin. After surgical insertion of a catheter in the hepatic artery, patients were treated with oxaliplatin 100 mg/m(2) HAI combined with FU + leucovorin IV according to the LV5FU2 protocol. Treatment was continued until disease progression or toxicity. Response was evaluated every 2 months. RESULTS: Twenty-eight patients were included, and 26 patients were treated. Two hundred courses of therapy were administered, and the median number of courses received was eight courses (range, zero to 20 courses). The most frequent toxicity consisted of neutropenia. The main toxicity related to HAI was pain. The intent-to-treat objective response rate was 64% (95% CI, 44% to 81%; 18 of 28 patients). With a median follow-up of 23 months, the median overall and disease-free survival times were 27 and 27 months, respectively. CONCLUSION: The combination of oxaliplatin HAI and FU + leucovorin according to the LV5FU2 protocol is feasible and effective in patients presenting with isolated hepatic metastases of colorectal cancer. 相似文献
999.
FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. 总被引:3,自引:0,他引:3
Silvia Hernández Elena López-Knowles Josep Lloreta Manolis Kogevinas Roberto Jaramillo Alex Amorós Adonina Tardón Reina García-Closas Consol Serra Alfredo Carrato Núria Malats Francisco X Real 《Clinical cancer research》2005,11(15):5444-5450
FGFR3 and Tp53 mutations have been proposed as defining two alternative pathways in the pathogenesis of transitional bladder cancer. FGFR3 mutations are associated with low-grade tumors and a favorable prognosis. Tp53 alterations are associated with advanced tumors and, possibly, with a poor prognosis. We focus here on the subgroup of T1G3 superficial tumors because they are a major clinical challenge. Patients (n = 119) were identified from a prospective study of 1,356 cases. Mutations in FGFR3 (exons 7, 10, and 15) and Tp53 (exons 4-9) were analyzed using PCR and direct sequencing. All cases were followed for recurrence and death. Survival was analyzed using Kaplan-Meier curves and multivariable Cox regression. FGFR3 mutations were detected in 20 (16.8%) tumors; 100 mutations in Tp53 were found in tumors from 78 (65.5%) cases. Multiple alterations in Tp53 were present in 19 tumors (16%). Inactivating mutations were present in 58% of tumors. The combined mutation distribution (FGFR3/Tp53) was: wt/wt (34.5%), mut/wt (7.6%), wt/mut (48.7%), and mut/mut (9.2%), indicating that the presence of either mutation did not depend on the other (P value = 0.767). FGFR3 and Tp53 mutations were not associated with clinicopathologic characteristics of patients and did not predict, alone or in combination, recurrence or survival. Taking the risk of the wt/wt group as reference, the mutation-associated risks of cancer-specific mortality were: mut/wt 1.42 (0.15-13.75), wt/mut 0.67 (0.19-2.31), mut/mut 1.62 (0.27-9.59). These molecular features support the notion that T1G3 tumors are at the crossroads of the two main molecular pathways proposed for bladder cancer development and progression. 相似文献
1000.
Carlos García-Girón Andrés García Palomo Carmen Alonso López Ángel León Carbonero Miguel Méndez Urena Encarna Adróver Cebrián Ramón Barceló Galíndez Mónica Arroyo Yustos José Álvarez Gallego 《Clinical & translational oncology》2005,7(6):244-249
Introduction This phase II study investigated the anti-tumour activity and toxicity of CPT-11 (250 mg/m2 i.v. infusion over 60 minutes)
administered every 2 weeks as second-line chemotherapy in patients with advanced colorectal cancer (CRC).
Material and methods Patients (n=63) with histology diagnosis of advanced CRC and proven resistance to previous fluoropyrimidine therapy were enrolled.
Results A total of 510 CPT-11 cycles were administered, with a mean of 8 cycles per patient (range: 1–32). The median relative dose
intensity was 93%. Partial response (PR) was obtained in 11 patients (17.5%; 95%CI: 8.1%–26.7%) and 29 patients (46.0%) showed
stable disease (clinical benefit of 63.5%). The median duration of response was 6.8 months (95%CI: 6.1–7.5 months), median
survival was 8.8 months (95%CI: 6.3–11.5 months) and median time to disease progression was 4.5 months (95%CI: 3.9–5.0 months).
Overall, this schedule of CPT-11 chemotherapy was well tolerated by the patient. Neutropenia was the most frequent grade 3/4
haematological toxicity (20.6% of patients and 4.1% of cycles). Neutropenia with concurrent fever or infection occurred in
7 patients (11.1%). Late onset diarrhoea was the most frequent grade 3/4 non-haematological toxicity (19.0% of patients and
2.3% of cycles). Other, lower-incidence, toxicities were anaemia, fever, infection, mucositis, nausea and vomiting. There
were no toxic deaths.
Conclusions We found that CPT-11, administered as 250 mg/m2 i.v. infusion over 60 minutes every 2 weeks, was active and well tolerated schedule in the second-line chemotherapy of advanced
CRC patients. This bi-weekly scheme could be used as an alternative to the weekly or the every-three-week schedule as well
as in combined therapies with other chemotherapeutic agents for the treatment of advanced, metastatic, CRC. 相似文献